MEDP insider August Troendle sells shares, retains major holdings

Rhea-AI Filing Summary

Medpace Holdings, Inc. (MEDP) CEO, director and 10% owner August J. Troendle reported open‑market sales of Medpace common stock. On 11/20/2025 he sold 6,830 shares at a weighted average price of $598.49, with individual trades ranging from $590.00 to $604.23. On 11/21/2025 he sold 21,858 shares at a weighted average price of $592.18, with trades ranging from $590.00 to $595.58. The transactions were effected under a limit order placed during an open window period. Following these sales, he directly beneficially owns 833,627 shares and indirectly beneficially owns 4,733,019 shares through Medpace Investors, LLC, where he has sole voting and investment control and may be deemed to beneficially own those securities to the extent of his pecuniary interest.

Insights

Equity Ownership and Governance Analyst

CEO and 10% owner executed open-market stock sales but retains a very large overall shareholding.

The filing reports that **August J. Troendle**, a **Director, CEO, and 10% owner** of **Medpace Holdings, Inc.**, executed open-market sales of Common Stock on 11/20/2025 and 11/21/2025. He sold **6,830** shares at a weighted average price of $598.49 and **21,858** shares at a weighted average price of $592.18, under a limit order placed during an open trading window. After these sales, he directly holds **833,627** shares and indirectly holds **4,733,019** shares through **Medpace Investors, LLC**.

The explanation notes that the reported prices are weighted averages of multiple trades within specified price ranges, and that detailed trade prices are available upon request. The filing states that he is the sole manager and controlling unit holder of **Medpace Investors, LLC**, with sole voting and investment control over those securities, and that he disclaims beneficial ownership beyond his economic interest. This means the reported transactions reduce his direct ownership but leave a substantial combined direct and indirect position.

Items to monitor include any future Form 4 filings that show additional sales or changes in his indirect holdings through **Medpace Investors, LLC**. The timing and size of subsequent transactions relative to this activity, particularly through the rest of 2025 and into following reporting periods, may help indicate whether these sales represent one-off portfolio adjustments or part of a broader pattern of ownership change.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Troendle August J.

(Last) (First) (Middle)

C/O MEDPACE HOLDINGS, INC.

5375 MEDPACE WAY

(Street)

CINCINNATI OH 45227

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/20/2025		S(1)		6,830	D	$598.49(2)	855,485	D
Common Stock	11/21/2025		S(1)		21,858	D	$592.18(3)	833,627	D
Common Stock								4,733,019	I	By Medpace Investors, LLC(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.

2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $590.00 to $604.23. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

3. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $590.00 to $595.58. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

4. The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Remarks:

	/s/ Stephen P. Ewald, Attorney-in-Fact for August J. Troendle	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Medpace (MEDP) report for August J. Troendle?

August J. Troendle, the CEO, director and 10% owner of Medpace Holdings, Inc. (MEDP), reported open‑market sales of Medpace common stock on 11/20/2025 and 11/21/2025.

How many Medpace (MEDP) shares did the CEO sell and at what prices?

He sold 6,830 shares on 11/20/2025 at a weighted average price of $598.49 and 21,858 shares on 11/21/2025 at a weighted average price of $592.18.

What were the trading price ranges for August J. Troendle’s Medpace (MEDP) stock sales?

The 11/20/2025 sales occurred in a range from $590.00 to $604.23, and the 11/21/2025 sales were in a range from $590.00 to $595.58.

How many Medpace (MEDP) shares does August J. Troendle own after these transactions?

After the reported sales, he directly beneficially owns 833,627 Medpace shares and indirectly beneficially owns 4,733,019 shares through Medpace Investors, LLC.

What is Medpace Investors, LLC’s role in August J. Troendle’s Medpace (MEDP) holdings?

Medpace Investors, LLC holds 4,733,019 Medpace shares. August J. Troendle is its sole manager and controlling unit holder, with sole voting and investment control, and he may be deemed to beneficially own those securities to the extent of his pecuniary interest.

Were August J. Troendle’s Medpace (MEDP) stock sales made under any specific trading instructions?

Yes. The transactions were effected pursuant to a limit order placed by him during an open window period.